About Us
AtrimusRx AB is a well-established, high-volume Swedish pharmaceutical company dedicated to securing continuous healthcare operations and critical patient treatment in the event of medicine shortages and market stockouts.
Founded in 2016, AtrimusRx has evolved into a key infrastructure provider within the Nordic healthcare ecosystem. With a proven track record of over 73,000 successfully managed orders, we operate as a financially solid, highly trusted partner to hospitals, pharmacies, and healthcare providers across Sweden and Europe.
We bridge global logistical gaps by deploying a unique combination of regulatory expertise, dual-licensed pharmaceutical capabilities, and cutting-edge digital infrastructure.
Our Core Operations & Services
To successfully safeguard healthcare continuity when global supply chains fail, AtrimusRx operates across three pillars:
1. Dual-Licensed Pharmaceutical Access (Wholesale & Pharmacy)
AtrimusRx holds comprehensive, official permits from the Swedish Medical Products Agency (Läkemedelsverket) for both Wholesale Distribution (Partihandel) and Community Pharmacy operations (Öppenvårdsapotek).
This unique dual authorization enables us to seamlessly import, manage, and distribute critical, foreign medicines (licensläkemedel) from premier international markets across the US and EEA directly to Swedish hospitals and pharmacies.
Our current product portfolio spans over 7,900 distinct pharmaceutical preparations.
2. Digital Healthcare Solutions & Shortage Tracking
We don’t just move physical products; we build the digital ecosystem that empowers medical professionals.
AtrimusRx is the pioneer behind proprietary digital tools used by prescribing physicians, including Sweden’s first shortage medicines app and the advanced national tracking platform RestnoteradeLakemedel.se.
These services structure real-time availability data, helping healthcare providers navigate, track, and mitigate critical drug shortages efficiently.
3. Advanced Extemporaneous/Compounding Manufacturing (Atrimus Px™)
When a needed dosage or strength does not exist on the global market, we manufacture it ourselves.
Operating at full commercial scale (TRL 9), our extemporaneous division utilizes advanced additive manufacturing (3D-printing) through our proprietary Atrimus Px™ framework.
This enables precise, tailored dosing for vulnerable patient groups—such as pediatrics, adult specialized care, and veterinary medicine—without relying on manual manipulation of adult medications.
A Strategic European Partner
Our established position and operational excellence are recognized at the highest levels of governance.
AtrimusRx is the selected Swedish industrial partner in the high-profile, EU-funded RoboPharma initiative (co-funded by the European Union’s EU4Health program).
Alongside European authorities, we are spearheading the integration of robotized dosage, AI-driven analysis, and automated workflows to build decentralized, agile manufacturing nodes that protect continental health security against future pandemics and global crises.
Corporate Profile
Established: 2016
Operational Scale: >73,000 handled orders, >7,900 active products in portfolio
Headquarters & Facilities: Fully validated, custom pharmaceutical facilities in Sollentuna, Sweden.
Regulatory Standing: Audited, inspected, and dual-licensed by the Swedish Medical Products Agency (Läkemedelsverket).